- $2.61bn
- $4.92bn
- $684.98m
- 34
- 47
- 57
- 42
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 612 | 582 | 664 | 739 | 685 |
Cost of Revenue | |||||
Gross Profit | 318 | 327 | 351 | 366 | 387 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 460 | 402 | 596 | 558 | 749 |
Operating Profit | 151 | 181 | 68.1 | 181 | -64.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 195 | 101 | 78.4 | 150 | -73.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 195 | 101 | 78.2 | 149 | -74.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 192 | 97.4 | 76.5 | 173 | -73.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 191 | 97 | 76 | 172 | -74.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.06 | 0.394 | 0.958 | 1.1 | 0.516 |
Dividends per Share |